|
2003
SPECIALTY PHARMACEUTICAL INVESTMENT CONFERENCE
MINING THE PIPELINE FOR
QUALITY COMPANIES
March 20, 2003 ~ The Princeton Club, NYC
15 West 43rd Street, between
Fifth and Sixth Avenues
SPEAKERS
Daniel
Glassman - President & CEO, Bradley Pharmaceutical
BRADLEY
PHARMACEUTICALS, INC., comprised of two operating units,
delivers respiratory, gastroenterology and nutritional brands
through KENWOOD THERAPEUTICS, and dermatology brands through
DOAK DERMATOLOGICS. Bradley’s
products include prescription and ethically-promoted
non-prescription drugs that are marketed in 31 markets
worldwide. By targeting unfilled marketing opportunities,
observing discipline within well-defined budgets and
introducing product line extensions to answer unmet needs,
Bradley has entered a vibrant growth stage -- seven new line
extensions to the Company’s key promoted product families
were launched beginning in September 2000.
Edward
Calesa - CEO, Women First Healthcare
Edward
F. Calesa co-founded Women First in November 1996 and has
served as a Director since that time. Mr. Calesa has served as
Chairman of the Board of Directors since December 1996. He
served as Women First's President and Chief Executive Officer
from November 1996 to January 1998 and resumed those roles in
July 2000. Mr. Calesa has an extensive background in
innovative health care marketing. In 1971, he co-founded and
served as Chairman of the Board of Health Learning Systems,
Inc. During his tenure at Health Learning Systems, Mr. Calesa
developed working relationships with many academic medical
specialists and medical organizations, including the National
Institutes of Health, National Board of Medical Examiners,
Educational Testing Services, Washington Business Group on
Health, Voluntary Hospitals of America, and numerous
pharmaceutical companies. Mr. Calesa sold Health Learning
Systems in December 1988 to WPP Group, plc. From January 1989
to November 1996, Mr. Calesa served as General Partner of an
investment partnership, Calesa Associates. Mr. Calesa holds an
M.B.A. in marketing from Fairleigh Dickinson University and a
B.A. in economics from Columbia College.
Mahendra Shah - CEO,
First Horizon Pharmaceuticals
Dr. Shah has been a director since 1993. Dr. Shah
became Chief Executive Officer in October 1999 and President
in January 2002. From 1991 to 2000, he was a Vice President of
EJ Financial Enterprises, Inc., which manages a fund that
invests in healthcare companies. Dr. Shah was also the
previous Chairman of Inpharmakon Corporation. He currently
serves on the board of Structural Bioinformatics Inc. and
Introgen Therapeutics. Dr. Shah has held various scientific
and management positions with Schering-Plough and Bristol
Myers-Squibb Company.
Dr. John R. Plachetka -
Chairman, President & CEO, Pozen
Prior to founding POZEN in 1996, Dr. Plachetka was vice
president of development at Texas Biotechnology Corporation
for two years, where he led the development of argatroban, a
novel thrombin blocker. Previously, he served for two years as
president and chief executive officer of Clinical Research
Foundation-America, a top-10 contract clinical research
company in the U.S. This was preceded by a nine-year career at
Glaxo Inc. where Dr. Plachetka held various executive
positions including director of cardiovascular clinical
research and led the U.S. development program for Imitrex®,
Trandate®, and a thromboxane antagonist. He also participated
in the development program for Zantac® tablets and injection.
Dr. Plachetka was formerly assistant professor of Pharmacy
Practice and Cardiovascular and Thoracic Surgery at the
University of Arizona. He earned his bachelor's degree in
pharmacy from the University of Illinois College of Pharmacy
and holds a doctor of pharmacy degree from the University of
Missouri-Kansas City.
Edward Saltzman -
President, Defined Health
Ed has devoted the majority of his 20+ years in the
healthcare industry to the identification, evaluation and
strategic development of healthcare business opportunities. At
Defined Health, Ed has directed thousands of opportunity
assessments covering hundreds of established markets and
development programs in pharmaceuticals, biotechnology,
medical devices, diagnostics and healthcare services. For the
past several years he has leveraged this experience in
advising the management of development stage, niche and
fully-integrated global pharmaceutical companies on business
development and corporate partnering issues. Before his
involvement with Defined Health, Ed was employed by the Ayerst
Laboratories unit of American Home Products, with
responsibilities for evaluation and forecasting of compounds
being considered for licensing. Prior to Ayerst, he managed
the Healthcare Information Center at FIND/SVP. Ed is a member
of the Licensing Executives Society and the New York Pharma
Forum and is a graduate of New York University.
Edward Kornreich -
Partner, Proskauer Rose
Ed Kornreich is a partner in Proskauer Rose LLP's
Health Care Department and serves in the New York City office.
Ed has practiced health care law for over twenty years. He
represents not-for-profit and for-profit hospitals, academic
medical centers, physician groups, physician management
companies, HMOs, venture capitalists and health care
entrepreneurs in, among other things, regulatory compliance
matters, mergers and acquisitions regarding health care
entities, managed care contracting, the development of
integrated health systems and physician organizations,
hospital purchases of physician practices, and joint venture
arrangements. His past experience reflects a blend of public
and private service and institutional and non-institutional
settings. Upon graduating from Harvard Law School, Ed worked
for the Legal Aid Society. He then entered private practice,
where he helped represent a major public hospital corporation
in a series of reimbursement disputes with the state and
federal governments, and counseled metropolitan hospitals and
nursing homes on reimbursement and operational issues.
Thereafter, Ed served as General Counsel of the St.
Luke's-Roosevelt Hospital Center, one of the largest teaching
hospitals in New York. Upon leaving the St. Luke's-Roosevelt
Hospital Center, Ed joined Proskauer as a partner in 1990.
David Lickrish - Analyst, Punk
Ziegel
David Lickrish is a member of the equity research team at
Punk, Ziegel & Company covering the specialty
pharmaceutical sector. Mr. Lickrish has more than five years
experience in research. Mr. Lickrish has a background in
Microbiology, and obtained a Bachelor of Commerce Degree from
the University of Guelph with honors in finance. Mr. Lickrish
is also a CFA Charterholder.
Joe Echols - Chairman, Crimson
Pharmaceuticals
Joe Echols began
his career in the pharmaceutical industry in 1969 after
graduation from the University of Georgia with a Bachelor’s
degree in marketing. His
first 14 years were in sales & sales management with
pharmaceutical divisions of Johnson & Johnson, and he was
a member of the original management team for the USA
subsidiary of Janssen Pharmaceutica.
The subsequent 12 years were spent with smaller and
start-up pharma companies, both OTC and prescription, in the
ophthalmic, analgesic, gastroenterology, respiratory and
related categories; in the capacities of general management,
sales management, marketing, trade relations, advertising
management and international business development. During this time, Echols formed the international division
for what is now Axcan Pharma.
Since the mid 1990’s, he has maintained an
independent pharmaceutical consulting business with his son,
involved in numerous projects in the USA and globally.
He was invited to join the Licensing Executives Society
in 1996 and remains active in this organization.
In 2001, he formed Aqueous Pharma Ltd., and acquired
innovative, patented technology from Dr. Frank Holly, one of
the world’s foremost scientists in the study of the human
tear and dry eye disorders.
This technology is the basis for four artificial tear
formulations to effectively treat all classifications of dry
eye syndrome, and Echols is currently engaged in
commercializing these products on a global basis.
William Brown - CFO, MGI Pharma
Bill Brown joined MGI PHARMA in June 1986 as
controller and since that time has held positions of
increasing responsibility in finance, accounting, business
development, strategic planning and investor relations. He was
promoted to his current position as chief financial officer
and secretary in 1999. Prior to his 15 years with MGI PHARMA
he was an audit manager at what is now Ernst & Young, an
international public accounting firm. In 1978, Mr. Brown
earned a bachelor's degree in education with majors in
chemistry and biology, and a master's degree in business
administration in 1981, both from the University of Minnesota.
He received his certified public accountant certification in
1981 and his certificate in management accounting in 1982.
Edward Jacobs - CFO,
SuperGen
Edward L. Jacobs was appointed Chief Business and Financial
Officer in October 2001, following serving as Executive Vice
President, Commercial Operations of SuperGen from 1999 to
2001. Most recently Mr. Jacobs served as President and Chief
Executive Officer of ETEX, a Cambridge, Mass.-based
biomaterials and drug delivery company. Prior to joining
SuperGen Mr. Jacobs served as Senior Vice President,
Commercial Operations at Sequus Pharmaceuticals, Inc. between
1997 and 1999. Between 1995 and 1997, Mr. Jacobs served as
President and Chief Executive Officer of Trilex
Pharmaceuticals Inc., now Titan Pharmaceuticals. Prior to his
association with Trilex, Mr. Jacobs served in a variety of
senior management positions with pharmaceutical companies,
including Chief Executive at Transplant Therapeutics Inc.,
Vice President and General Manager of Syncor International
Inc., Vice President at NeoRX Corporation, Business Director
of Pharmacia (Adria Labs, Inc.) and Johnson & Johnson
(McNeil). Mr. Jacobs received a B.A. in Political
Science/Journalism from California State University at
Northridge.
Gregory Weaver - CFO,
Nastech Pharmaceutical
Nastech
participates in the drug delivery industry estimated at $12
billion in revenues. Conventional methods of drug delivery
include oral administration and injections. Newer delivery
methods include improved versions of the above and other novel
systems such as nasal, transdermal and pulmonary systems,
among others. These newer methods of drug delivery often
provide greater safety and efficacy, fewer side effects,
improved patient compliance and lower healthcare costs to the
patient.
Timothy Morris - CFO,
Questcor Pharmaceuticals
Mr. Morris joined the Company in September 2001 as the Vice
President of Finance & Administration, Chief Financial
Officer. Prior to joining Questcor, Mr. Morris held several
senior financial positions over the last eight years at a
variety of pharmaceutical and technology venture backed
companies including RiboGene, Inc, the predecessor to Questcor,
where he served in the same capacity. He also served as the
Chief Financial Officer for InterPro Business Solutions, Inc
and Utility.com; and as Chief Accounting Officer for Glycomed
Incorporated. Mr. Morris also had eight years experience with
Ernst & Young, LLC, where he focused on biotech and
technology start-ups. Mr. Morris is a certified public
accountant and has a business degree from California State
University, Chico.
Andrew Forman - Managing Director,
Healthcare Research,
Friedman, Billings, Ramsey & Co., Inc.
Andrew
S. Forman joined FBR & Co. in July 2001 as a senior
analyst and managing director in the healthcare research
group. Mr. Forman's concentration is the specialty
pharmaceutical sector, which includes generic drug companies,
drug delivery companies, and emerging pharmaceutical
companies. He also provides leadership to FBR & Co.'s
analysts in the European pharmaceutical and biotechnology
sectors. Mr. Forman joined FBR & Co. from UBS Warburg
where he covered specialty pharmaceutical companies for five
years. In 2000, he ranked #9 in the Institutional Investor's
poll in the specialty pharmaceutical category. In 1999, he was
ranked #1 analyst by Reuters Survey of small to mid-size
pharmaceutical companies, and chosen as one of 10 analysts on
Zack's All Star Team for health care stock picking in
1999-2000. Mr. Forman began his Wall Street career in 1996
when he joined Dillon Read as a drug delivery analyst. Prior
to that, he spent 10 years in the industry. He was a
pharmaceutical sales representative for Bristol Myers,
business development manager in the Biotechnology Systems
Division of Du Pont, and later director of business
development at Cygnus, a drug delivery company, where he was
responsible for forging alliances with pharmaceutical
companies. Mr. Forman received his B.A. in physiology from
Rutgers, and his MBA from Columbia Business School.
David Blume -
Managing Director & Co-Founder, Edgemont Capital Partners
Prior to founding Edgemont, I ran the Specialty
Pharmaceuticals, Pharmaceutical Outsourcing and Health
Information Technology Coverage Teams in The Lehman Brothers
Healthcare Group. Over
the years, my clients have ranged in size from start-ups to
Fortune 50 companies. In representing these companies, I've
completed some large transactions, including representing the
seller in the largest CRO transaction and the buyer in one of
the largest non-pharmaceutical healthcare transactions of all
time. Yet despite these successes, I have always enjoyed most
working with smaller and entrepreneurial companies. Advising
venture companies at Patricof & Co. (now Apax Partners) in
the early 1990's provided me with strong insight into earlier
stage companies and I have found over the years that my most
rewarding professional experiences have resulted from working
with emerging, high growth and dynamic companies. I am also a
board member of the Rutgers University Venture Action
Committee (RVAC).
Eran
Broshy - CEO, Ventiv Health
Mr.
Broshy is a widely recognized authority and frequent speaker
on strategic issues in pharmaceuticals and healthcare. Prior
to joining Ventiv he served as the partner responsible for the
healthcare practice of The Boston Consulting Group (BCG)
across the Americas. During his fourteen-year tenure at BCG,
Mr. Broshy consulted widely with senior executives from a
number of the major global pharmaceutical manufacturers,
managed care organizations, and academic medical centers, and
advised on a range of strategic, organizational and
operational issues. Mr. Broshy has also served as President
and Chief Executive Officer of Coelcanth Corporation, a
privately-held biotechnology company. Mr. Broshy is a graduate
of Harvard University (MBA), Stanford University (MS), and
Massachusetts Institute of Technology (BS).
Dr. Roger Harrison - CEO,
Antares Pharma
Dr. Harrison
joined Antares Pharma as Chief Executive Officer, President
and a member of the Board of Directors in March 2001. Since
1984, Dr. Harrison held various positions at Eli Lilly and
Company, with his most recent role being Director of Alliance
Management from May 1999 until March 2001. Other positions at
Eli Lilly and Company included Global Product Team Leader from
March 1997 to May 1999 and Director, Development Projects
Management and Technology Development and Planning from
September 1993 to May 1997. He is the author of twelve
publications, has contributed to four books and holds nine
patents. Dr. Harrison earned a Ph.D. in organic chemistry and
a B.Sc. in chemistry from Leeds University in the United
Kingdom and conducted postdoctoral research work at Zurich
University in Switzerland.
Atul M. Mehta -
President & CEO, Elite Pharmaceuticals
Dr.
Atul M. Mehta, President and CEO, a renowned scientist in the
field of oral controlled release dosage form development with
over 15 years of experience, and inventor in 10 US patents,
founded Elite Laboratories in 1990. Dr. Mehta is assisted by a Board of Directors and a prestigious advisory
board whose expertise encompasses such diverse areas as
science, medicine, pharmacy, marketing, and sales.
Sidney Pestka, M.D. -
Chairman & CSO, PBL Therapeutics
PBL Therapeutics was formed to commercialize the ideas and
utilize the expertise of Dr. Sidney Pestka, an internationally
recognized scientist with over three decades of pioneering
work in the research and development of proteins and protein
biopharmaceuticals. Dr. Pestka, the Company's Chairman and
Chief Scientific Officer, was the first to clone mature
interferons and the first to develop a commercialized
recombinant biotherapeutic-Roferon A-while at the Roche
Institute of Molecular Biology of Hoffmann-La Roche, where he
spent 17 years leading these efforts. Dr. Pestka also serves
as a Professor and Chairman of the Department of Molecular
Genetics, Microbiology and Immunology at the Robert Wood
Johnson Medical School of the University of Medicine and
Dentistry of New Jersey. He is presently the named inventor on
over 100 U.S. and foreign patents and has 400 original
research articles in his name.
|
